Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

For Its Latest Epigenetics Deal, Celgene Takes Option To Buy Acetylon

This article was originally published in The Pink Sheet Daily

Executive Summary

A $100 million, non-dilutive investment will keep Acetylon off the market, giving Celgene the right to buy it for a minimum of $500 million up-front within a pre-determined time window. For now, Acetylon retains all rights to its pipeline, including Phase Ib multiple myeloma drug ACY-1215.

You may also be interested in...



Celgene Looks To Longer Revlimid Duration In MM To Expand Revenue

At ASH, Celgene detailed the results of its MM-020 study for continuous use of Revlimid in newly diagnosed multiple myeloma patients. That’s just one of several treatment strategies that could significantly increase patient time on the drug – and Revlimid revenues.

Deals of the Week: Is Astex Settling For An Underpriced Buyout?

A new life sciences hedge fund operated by two former associates of activist investor Carl Icahn is challenging Otsuka’s takeover of cancer drug developer Astex. Also, Johnson & Johnson’s London Innovation Center announced four alliances, Celgene took another option on one of its investments and Takeda teamed up with New York research institutions to form a new discovery institute.

Fibrosis/Cancer Start-up Seeded By Celgene Begins To Take Shape

Bay City Capital will back the PharmAkea with a $10 million Series A financing. Celgene also holds an undisclosed equity stake in the new company, under a three-year, $35 million R&D funding agreement with options to extend the arrangement or acquire the firm.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel